Send to

Choose Destination
Curr Opin Immunol. 2008 Aug;20(4):479-85. doi: 10.1016/j.coi.2008.05.010. Epub 2008 Jul 9.

When binding is enough: nonactivating antibody formats.

Author information

Genmab, Yalelaan 60, Utrecht, The Netherlands.


Most therapeutic antibodies currently used in the clinic are based on the human IgG1 format, which is a bivalent molecule that efficiently interacts with the immune system's effector functions. In clinical applications where binding to the target alone is sufficient for therapeutic efficacy; however, engagement of the immune system is not required and may even cause unwanted side-effects. Likewise, bivalent binding to the target may negatively influence the therapeutic efficacy of an antibody. Here we discuss the state of the art for antibody-based therapeutics, designed to be nonactivating (i.e. do not engage the innate immune system's effector functions), in both monovalent and bivalent formats.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center